source
- Ultragenyx secures first gene therapy approval for GSDIa as Sanfilippo asset decision pendingUltragenyx received accelerated FDA approval for its gene therapy DTX401, marketed as Genglycos, to treat glycogen storage disease type Ia (GSDIa). The approval comes as the company awaits a secon…
- Optimal Balance Pharmacy recalls one lot of compounded glutathione injection over high endotoxin levelsOptimal Balance Pharmacy announced a voluntary recall of a single lot of its compounded glutathione 200 mg/mL multi‑dose vials. The recall was triggered after internal testing detected elevated bac…